Volume 97, Issue 5 pp. 903-904
EDITORIAL COMMENT

Paravalvular leak after TAVR: remarkable improvement but not the time to shift focus

Dhruv Mahtta DO, MBA

Dhruv Mahtta DO, MBA

Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA

Section of Cardiology, Department of Medicine, Michael E. Debakey VA Medical Center, Houston, Texas, USA

Search for more papers by this author
Hani Jneid MD

Corresponding Author

Hani Jneid MD

Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA

Section of Cardiology, Department of Medicine, Michael E. Debakey VA Medical Center, Houston, Texas, USA

Correspondence

Hani Jneid, MD, Section of Cardiology, Department of Medicine, Baylor College of Medicine and the Michael E. DeBakey VAMC, Houston TX 77030.

Email: [email protected]

Search for more papers by this author
First published: 14 April 2021

Key Points

  • Significant paravalvular leak (PVL) among patients undergoing transcatheter aortic valve replacement (TAVR) portends a poor prognosis and is often associated with increased mortality.
  • TAVR with the latest generation balloon-expandable valve platform, Edwards SAPIEN 3 Ultra, is associated with lower incidence of PVL (including lower rates of mild PVL and zero incidence of moderate and severe PVL) compared to its predecessor, the SAPIEN 3 valve platform.
  • The similar safety profile, comparable deliverability, and lower PVL observed with the Edwards SAPIEN 3 Ultra system will likely lead to its increased adoption in clinical practice. Future studies are needed to examine its long-term clinical outcomes and further decipher the procedural and patient factors associated with PVL.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.